Corrigendum to ‘Race, ethnicity, F8 variants and inhibitor risk: Analysis of the “My Life Our Future” Hemophilia A database’ [Journal of Thrombosis and Haemostasis Volume 21, Issue 4, April 2023, Pages 800-813] (Journal of Thrombosis and Haemostasis (2023) 21(4) (800–813), (S1538783622182577), (10.1016/j.jtha.2022.12.017))

Research output: Contribution to journalComment/debate

Abstract

The authors regret the need to update the acknowledgements and change the below paragraphs as follows: Original Introduction, paragraph 3: The “My Life Our Future” (MLOF) Research Repository is the result of a collaboration between the hemophilia community in the United States, their respective hemophilia treatment centers (HTCs), the Bloodworks Northwest Research Institute (BWNW), and the American Thrombosis and Hemostasis Network (ATHN), carried out with initial funding from Biogen (now Bioverativ/Sanofi, Inc) [4,5]. Under this program, individuals were able to submit (through their HTC) a blood sample, from which DNA was extracted and analyzed to determine whether the participant carried a genetic mutation associated with a bleeding disorder, e.g., hemophilia A or B, von Willebrand disease, etc. Participation in research by donating DNA and plasma fractions of these blood samples and making their clinically relevant data available to researchers was offered, but not required, as part of this initiative. Through a competitive application process, access to the MLOF and ATHN databases was granted to several research groups, each of which proposed research questions that could be uniquely addressed using data and/or samples from this Repository. The ATHN/MLOF Repository currently contains the largest dataset in the world containing F8 DNA sequences linked to clinical data for HA subjects. Revised Introduction, paragraph 3: The “My Life Our Future” (MLOF) Research Repository is the result of a collaboration between the hemophilia community in the United States, their respective hemophilia treatment centers (HTCs), Bloodworks Northwest (BWNW), the National Hemophilia Foundation, and the American Thrombosis and Hemostasis Network (ATHN), carried out with initial funding from Biogen/Bioverativ [4,5]. Under this program, individuals were able to submit (through their HTC) a blood sample, from which DNA was extracted and analyzed to determine whether the participant carried a genetic variant associated with hemophilia A or B. Participation in research by donating DNA and blood samples and making their clinically relevant data available to researchers was offered, but not required, as part of this initiative. Through a competitive application process, access to the MLOF and ATHN databases was granted to several research groups, each of which proposed research questions that could be uniquely addressed using data and/or samples from this Repository. The ATHN/MLOF Repository currently contains the largest dataset in the world containing F8 DNA sequences linked to clinical data for HA subjects. Original Acknowledgments: We are grateful to the My Life Our Future Executive Committee that approved this project and to ATHN for providing the data. Special thanks to Ms Shelley Fletcher and Dr Jill Johnsen (BWNW) for assistance with data cleaning of the original ATHN/MLOF datasets. Revised Acknowledgments: The My Life, Our Future Research Repository is a collection of genetic and phenotypic data and samples developed from the My Life, Our Future (MLOF) national genotyping program, which was a partnership with the American Thrombosis Hemostasis Network, Bloodworks Northwest, and the National Hemophilia Foundation with financial support from Biogen/Bioverativ. The MLOF Research Repository was established through engagement with the blood disorders community to co-create a repository of genotypic data about people with hemophilia, which can be used to support research. More than 9,000 participants in MLOF consented to contribute their genetic data and biological samples to create the MLOF Research Repository. The MLOF Research Repository acknowledges the dedicated efforts all of the participants in MLOF, and the hemophilia treatment centers for their significant contributions to the MLOF Research Repository. Special thanks to Ms Shelley Fletcher and Dr Jill Johnsen (BWNW) for assistance with data cleaning of the original ATHN/MLOF datasets. The MLOF Research Repository has received financial support from the American Thrombosis and Hemostasis Network, the National Hemophilia Foundation, Bloodworks Northwest, the Washington Center for Bleeding Disorders, and Sanofi. The content of this manuscript is solely the responsibility of the authors and does not necessarily represent the views of the My Life, Our Future Research Repository project, or its partners. The authors would like to apologise for any inconvenience caused.

Original languageEnglish
Pages (from-to)1684-1685
Number of pages2
JournalJournal of Thrombosis and Haemostasis
Volume21
Issue number6
DOIs
StatePublished - Jun 2023
Externally publishedYes

Fingerprint

Dive into the research topics of 'Corrigendum to ‘Race, ethnicity, F8 variants and inhibitor risk: Analysis of the “My Life Our Future” Hemophilia A database’ [Journal of Thrombosis and Haemostasis Volume 21, Issue 4, April 2023, Pages 800-813] (Journal of Thrombosis and Haemostasis (2023) 21(4) (800–813), (S1538783622182577), (10.1016/j.jtha.2022.12.017))'. Together they form a unique fingerprint.

Cite this